Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Psychosocial factors have been described as affecting cellular immune measures in healthy subjects. In patients with early breast cancer we explored bi-directional psycho-immune effects to determine whether subjective burden has an impact on immune measures, and vice versa. Patients (n = 239) operated for early breast cancer and randomized into International Breast Cancer Study Group (IBCSG) adjuvant clinical trials were assessed immediately before the beginning of adjuvant treatment (baseline) and 3 and 6 months thereafter, at the beginning of the corresponding treatment cycle. Cellular immune measures (leukocytes, lymphocytes, lymphocyte subset counts), markers of activation of the cellular immune system (beta2-microglobulin, soluble interleukin-2 receptor serum levels), and self-report subjective burden (global indicators of physical well-being, mood, coping effort) were assessed concurrently. The relationship between subjective burden and gradients of immune measures was investigated with regression analyses controlling for adjuvant treatment. There was a pattern of small negative associations between all variables assessing subjective burden before the beginning of adjuvant therapy with the gradients of the markers of activation of the cellular immune system and NK cell counts. In particular, better mood predicted a decline in the course of beta2-microglobulin and IL-2r at months 3 and 6. The gradient of beta2-microglobulin was associated with mood and coping effort at month 3. However, the effect sizes were very small. In conclusion, in this explorative investigation, there was an indication for subjective burden affecting and being affected by markers of activation of the cellular immune system during the first 3 and 6 months of adjuvant therapy. The question of clinical significance remains unanswered. These associations have to be investigated with refined assessment tools and schedules.
Sabbioni
Marzio E E
ME
Medical Division Lory-Haus, University Hospital, Inselspital, Berne, Switzerland. marzio.sabbioni@insel.ch
Bernhard
Jürg
J
Siegrist
Hans-Peter
HP
Schmitz
Shu-Fang Hsu
SF
Gertsch
Monica Castiglione
MC
Thürlimann
Beat
B
Bonnefoi
Hervé
H
Perey
Lucien
L
Herrmann
Richard
R
Goldhirsch
Aron
A
Hürny
Christoph
C
D000223:Adaptation, Psychological; D000328:Adult; D000339:Affect; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000523:psychology*; D017024:Chemotherapy, Adjuvant; D017281:Cost of Illness; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007694:Killer Cells, Natural; D008875:Middle Aged; D012649:Self Concept